Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol
Medicine
[키워드] acute respiratory distress
administration
Adverse
ARDS
case sery
characterized
clinical condition
Clinical improvement
clinical response
clinical status
clinically
Collection
complete recovery
Course
COVID-19
COVID19
Critically ill patient
Cytokine storm syndrome
death
develop
disease
drug
Evidence
Evolution
help
Host
hyperinflammation
ICU
identify
immune-mediated diseases
Infection
inflammation response
inhibitor
JAK1
JAK2
Laboratory
mechanical ventilation
modify
Mortality
non-invasive ventilation
organ function
Oxygen requirement
pandemic
PaO
Patient
primary endpoint
progressive COVID-19
progressive disease
reduce
Research
respiratory
Respiratory distress syndrome
Respiratory function
respiratory impairment
ruxolitinib
ruxolitinib treatment
secondary endpoint
Serious Adverse Event
severe COVID-19
subsequent
subset
syndrome
the disease
therapeutic option
treat
Treatment
ventilatory support
viral-induced
was recorded
were assessed
with COVID-19
[DOI] 10.3389/fmed.2020.00466 PMC 바로가기 [Article Type] Medicine
[DOI] 10.3389/fmed.2020.00466 PMC 바로가기 [Article Type] Medicine